open access
Immune checkpoint inhibitors as drugs or drug candidates in neoplastic diseases
Affiliations- Zakład Hematologii Doświadczalnej Uniwersytetu Medycznego w Łodzi, Polska
open access
Abstract
Despite of great progress in anti-neoplastic treatment the several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanism. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged in the immune control point. Immunotherapy with immune checkpoint inhibitors has emerged as promising modality of tumors showing response to several antigens, e.g. anti-CTLA-4 or PD1-PDL1 monoclonal antibodies. In this review we demonstrate the state in the field on this modality of anti-neoplastic treatment.
Abstract
Despite of great progress in anti-neoplastic treatment the several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanism. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged in the immune control point. Immunotherapy with immune checkpoint inhibitors has emerged as promising modality of tumors showing response to several antigens, e.g. anti-CTLA-4 or PD1-PDL1 monoclonal antibodies. In this review we demonstrate the state in the field on this modality of anti-neoplastic treatment.
Keywords
Cell cycle; Inhibitors; Targeted therapy; Checkpoint
About this articleTitle
Immune checkpoint inhibitors as drugs or drug candidates in neoplastic diseases
Journal
Issue
Pages
155-162
Published online
2016-04-01
Page views
108
Article views/downloads
368
DOI
10.1016/j.achaem.2016.04.008
Bibliographic record
Acta Haematol Pol 2016;47(2):155-162.
Keywords
Cell cycle
Inhibitors
Targeted therapy
Checkpoint
Authors
Aleksandra Mędra
Agata Majchrzak
Piotr Smolewski